BlueCrest Capital Management’s Core Laboratories CLB Stock Holding History

BlueCrest Capital Management’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-88,000	Closed	-$1.94M	–	217
2023 Q1	$1.94M	Buy	+88,000	New	+$2.06M	0.06%	111
2019 Q2	–	Sell	-3,300	Closed	-$227K	–	521
2019 Q1	$227K	Buy	+3,300	New	+$221K	0.01%	873
2018 Q1	–	Sell	-20,173	Closed	-$2.21M	–	1498
2017 Q4	$2.21M	Buy	+20,173	New	+$2.01M	0.06%	257
2016 Q1	–	Sell	-3,564	Closed	-$388K	–	816
2015 Q4	$388K	Sell	3,564 -8,544	-71%	-$978K	0.02%	657
2015 Q3	$1.21M	Sell	12,108 -14,600	-55%	-$1.59M	0.04%	402
2015 Q2	$3.05M	Buy	+26,708	New	+$3.24M	0.09%	241

Other funds holding CLB

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlueCrest Capital Management's CLB Position: Q2 2023 in Review

BlueCrest Capital Management sold out of Core Laboratories (CLB) in Q2 2023, closing a stake of 88,000 shares — an estimated $1.94M sold.

BlueCrest Capital Management first reported a position in CLB in Q2 2015 and held it in 6 quarters. The position peaked at $3.05M in Q2 2015. 164 funds tracked by Wall St. Rank hold CLB as of Q2 2023.

BlueCrest Capital Management reported no remaining Core Laboratories position as of Q2 2023 after selling out during the quarter.
BlueCrest Capital Management sold 88,000 Core Laboratories shares in Q2 2023, an estimated $1.94M.
BlueCrest Capital Management first reported a position in Core Laboratories in Q2 2015 and held it in 6 quarters.
BlueCrest Capital Management's Core Laboratories position peaked at $3.05M in Q2 2015.
164 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2023.

Based on BlueCrest Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.